The global Rare Disease Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Rare Disease Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Rare Disease Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Rare Disease Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Rare Disease Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Shire
Amgen, Inc.
Deciphera
Atara Biotherapeutics
ProQR

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
>1‰
0.65‰～1‰
<0.1‰

Segment by Application
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others